Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population | springermedicine.com

Springer Medicine

Top

Frontiers of Medicine

Published in:

01-12-2016 | Research Article

Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population

Authors: Xin Du, Daobin Zhou

Published in: Frontiers of Medicine | Issue 4/2016

Login to get access

Title: Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
Authors: Xin Du
Daobin Zhou
Publication date: 01-12-2016
Publisher: Higher Education Press
Published in: Frontiers of Medicine / Issue 4/2016
Print ISSN: 2095-0217
Electronic ISSN: 2095-0225
DOI: https://doi.org/10.1007/s11684-016-0472-9

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties